Dozens of state and local governments are suing drug companies and pharmacy benefit managers, alleging that they’re unfairly hiking the price of insulin.
The plaintiffs say they’re fighting for patients. They’re less forthcoming about the fact that they’ve profited handsomely from the system they’re now decrying. For years, these cities and states have insisted on a cut—if not all—of the rebates that these pharmacy benefit managers extract from drug makers when negotiating over whether and how to cover specific drugs.
Nothing contained in this blog is to be construed as necessarily reflecting the views of the Pacific Research Institute or as an attempt to thwart or aid the passage of any legislation.
Insulin Lawsuits Obscure A Dirty Business
Sally C. Pipes
Dozens of state and local governments are suing drug companies and pharmacy benefit managers, alleging that they’re unfairly hiking the price of insulin.
The plaintiffs say they’re fighting for patients. They’re less forthcoming about the fact that they’ve profited handsomely from the system they’re now decrying. For years, these cities and states have insisted on a cut—if not all—of the rebates that these pharmacy benefit managers extract from drug makers when negotiating over whether and how to cover specific drugs.
Read the full article at Forbes
Nothing contained in this blog is to be construed as necessarily reflecting the views of the Pacific Research Institute or as an attempt to thwart or aid the passage of any legislation.